Safety and immunogenicity of a new heat-inactivated hepatitis B virus vaccine in adult recipients

A new heat inactivated HBV vaccine has been evaluated for safety and immunogenicity in 203 adult recipients. The vaccine was found to be safe and highly immunogenic. Three doses of 3 μg given at 0, 1 and 6 months, resulted in 96% seroconversion. Three doses of 3 μg given at 0, 1 and 2 months produced, more rapidly, seroconversion in 92% of those imunized. Antibody to a pre-S determinant developed in four of six subjects tested.